Neostigmine and edrophonium for reversal of pipecuronium neuromuscular blockade

Ferguson A, Egerszegi P, Bevan DR. Neostigmine, pyridostigmine, and edrophonium as antagonists of pancuronium. Anesthesiology 1980; 53: 390–4.

Naguib M, Abdulatif M, Absood GH. Accelerated reversal of atracurium blockade with priming doses of edrophonium. Anesthesiology 1987; 66: 397–400.

Engbaek J, Ording H, Ostergaard D, Viby-Mogensen J. Edrophonium and neostigmine for reversal of the neuromuscular blocking effect of vecuronium. Acta Anaesthesiol Scand 1985; 29: 544–6.

Boros M, Szenohradszky J, Kertesz A, Marosi GY, Tutsek L. Clinical experiences with pipecuronium bromide. Acta Chir Hung 1983; 24: 207–14.

Wierda JMKH, Richardson FJ, Agoston S. Dose-response relation and time course of action of pipecuronium bromide in humans anesthetized with nitrous oxide and isoflurane, halothane, or droperidol and fentanyl. Anesth Analg 1989; 68: 208–13.

Breen PJ, Doherty WG, Donati F, Bevan DR. The potencies of edrophonium and neostigmine as antagonists of pancuronium. Anaesthesia 1985; 40: 844–7.

Viby-Mogensen J. Clinical evaluation of neuromuscular transmission. Br J Anaesth 1982; 54: 209–23.

Ali HH, Kitz RJ. Evaluation of recovery from non-depolarizing nueromuscular block using a digital neuromuscular transmission analyzer: preliminary report. Anesth Analg 1973; 52: 740–3.

Karpati E, Biro K. Pharmacological study of a new competitive neuromuscular blocking steroid, pipecurium bromide. Arzneimittelforschung 1980; 30: 346–54.

Boros M, Szenohradszky J, Marsoi Y, Toth I. Comparative clinical study of pipecurium bromide and pancuronium bromide. Arzneimittelforschung 1980; 30: 389–93.

Bevan DR. Reversal of pancuronium with edrophonium. Anaesthesia 1979; 34: 614–9.

Cronnelly R, Morris RB, Miller RD. Edrophonium: duration of action and atropine requirement in humans during halothane anesthesia. Anesthesiology 1982; 57: 261–6.

Lavery GG, Mirakhur RJ, Gibson FM. A comparison of edrophonium and neostigmine for the antagonism of atracurium-induced neuromuscular block. Anesth Analg 1985; 64: 867–70.

Rupp SM, McChristian JW, Miller RD, Taboada JA, Cronnelly R. Neostigmine and edrophonium antagonism of varying intensity neuromuscular blockade induced by atracurium, pancuronium or vecuronium. Anesthesiology 1986; 64: 711–7.

Sanfilippo M, Vilardi V, Fierro G, Rosa G, Pelaia P, Gasparetto A. Neostigmine and edrophonium as antagonists of atracurium and pancuronium. Acta Anaesthesiol Scand 1988; 32: 437–40.

Astley BA, Hughes R, Payne JP. Antagonism of atracurium-induced neuromuscular blockade by neostigmine or edrophonium. Br J Anaesth 1986; 58: 1290–5.

Jones RM, Pearce AC, Williams JP. Recovery characteristics following antagonism of atracurium with neostigmine or edrophonium. Br J Anaesth 1984; 56: 453–7.

Smith CE, Donati F, Bevan DR. Dose-response relationships for edrophonium and neostigmine as antagonists of atracurium and vecuronium neuromuscular blockade. Anesthesiology 1989; 71: 37–43.

Donati F, McCarroll SM, Antzaka C, McCready D, Bevan DR. Dose-response curves for edrophonium, neostigmine, and pyridostigmine after pancuronium and d-tubocurarine. Anesthesiology 1987; 66: 471–6.

Fahey MR, Morris RB, Miller RD, Sohn YJ, Cronnelly R. Clinical pharmacology of ORG NC45 (Norcuron TM): a new nondepolarizing muscle relaxant. Anesthesiology 1981 ; 55: 6–11.

Graham GG, Morris R, Pybus DA, Torda TA, Woodey R. Relationship of train-of-four ratio to twitch depression during pancuronium-induced neuromuscular blockade. Anesthesiology 1986; 65: 579–83.

Donati F, Ferguson A, Bevan DR. Twitch depression and train-of-four ration after antagonism of pancuronium with edrophonium, neostigmine, or pyridostigmine. Anesth Analg 1983; 62: 314–6.